Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine
Identifieur interne : 002987 ( Pmc/Checkpoint ); précédent : 002986; suivant : 002988Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine
Auteurs : Christopher Burrell ; Robert Booy ; Nicholas Wood ; Anne-Marie Egan ; David Taverner ; Ken Williams ; Winston Liauw ; Alan Moskwa ; Stephanie Pepin-Covatta ; Melanie SavilleSource :
- Influenza and Other Respiratory Viruses [ 1750-2640 ] ; 2008.
Abstract
Url:
DOI: 10.1111/j.1750-2659.2008.00039.x
PubMed: 19453468
PubMed Central: 4634696
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:4634696Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine</title>
<author><name sortKey="Burrell, Christopher" sort="Burrell, Christopher" uniqKey="Burrell C" first="Christopher" last="Burrell">Christopher Burrell</name>
<affiliation><nlm:aff id="a1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="a2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Booy, Robert" sort="Booy, Robert" uniqKey="Booy R" first="Robert" last="Booy">Robert Booy</name>
<affiliation><nlm:aff id="a3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wood, Nicholas" sort="Wood, Nicholas" uniqKey="Wood N" first="Nicholas" last="Wood">Nicholas Wood</name>
<affiliation><nlm:aff id="a3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Egan, Anne Arie" sort="Egan, Anne Arie" uniqKey="Egan A" first="Anne-Marie" last="Egan">Anne-Marie Egan</name>
<affiliation><nlm:aff id="a3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Taverner, David" sort="Taverner, David" uniqKey="Taverner D" first="David" last="Taverner">David Taverner</name>
<affiliation><nlm:aff id="a4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Williams, Ken" sort="Williams, Ken" uniqKey="Williams K" first="Ken" last="Williams">Ken Williams</name>
<affiliation><nlm:aff id="a5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Liauw, Winston" sort="Liauw, Winston" uniqKey="Liauw W" first="Winston" last="Liauw">Winston Liauw</name>
<affiliation><nlm:aff id="a5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Moskwa, Alan" sort="Moskwa, Alan" uniqKey="Moskwa A" first="Alan" last="Moskwa">Alan Moskwa</name>
<affiliation><nlm:aff id="a6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pepin Ovatta, Stephanie" sort="Pepin Ovatta, Stephanie" uniqKey="Pepin Ovatta S" first="Stephanie" last="Pepin-Covatta">Stephanie Pepin-Covatta</name>
<affiliation><nlm:aff id="a7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Saville, Melanie" sort="Saville, Melanie" uniqKey="Saville M" first="Melanie" last="Saville">Melanie Saville</name>
<affiliation><nlm:aff id="a7"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19453468</idno>
<idno type="pmc">4634696</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634696</idno>
<idno type="RBID">PMC:4634696</idno>
<idno type="doi">10.1111/j.1750-2659.2008.00039.x</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">000278</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000278</idno>
<idno type="wicri:Area/Pmc/Curation">000278</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000278</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002987</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002987</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine</title>
<author><name sortKey="Burrell, Christopher" sort="Burrell, Christopher" uniqKey="Burrell C" first="Christopher" last="Burrell">Christopher Burrell</name>
<affiliation><nlm:aff id="a1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="a2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Booy, Robert" sort="Booy, Robert" uniqKey="Booy R" first="Robert" last="Booy">Robert Booy</name>
<affiliation><nlm:aff id="a3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wood, Nicholas" sort="Wood, Nicholas" uniqKey="Wood N" first="Nicholas" last="Wood">Nicholas Wood</name>
<affiliation><nlm:aff id="a3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Egan, Anne Arie" sort="Egan, Anne Arie" uniqKey="Egan A" first="Anne-Marie" last="Egan">Anne-Marie Egan</name>
<affiliation><nlm:aff id="a3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Taverner, David" sort="Taverner, David" uniqKey="Taverner D" first="David" last="Taverner">David Taverner</name>
<affiliation><nlm:aff id="a4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Williams, Ken" sort="Williams, Ken" uniqKey="Williams K" first="Ken" last="Williams">Ken Williams</name>
<affiliation><nlm:aff id="a5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Liauw, Winston" sort="Liauw, Winston" uniqKey="Liauw W" first="Winston" last="Liauw">Winston Liauw</name>
<affiliation><nlm:aff id="a5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Moskwa, Alan" sort="Moskwa, Alan" uniqKey="Moskwa A" first="Alan" last="Moskwa">Alan Moskwa</name>
<affiliation><nlm:aff id="a6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pepin Ovatta, Stephanie" sort="Pepin Ovatta, Stephanie" uniqKey="Pepin Ovatta S" first="Stephanie" last="Pepin-Covatta">Stephanie Pepin-Covatta</name>
<affiliation><nlm:aff id="a7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Saville, Melanie" sort="Saville, Melanie" uniqKey="Saville M" first="Melanie" last="Saville">Melanie Saville</name>
<affiliation><nlm:aff id="a7"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Influenza and Other Respiratory Viruses</title>
<idno type="ISSN">1750-2640</idno>
<idno type="eISSN">1750-2659</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><bold>Background </bold>
The 2005 southern hemisphere formulation of the inactivated split‐virion influenza vaccine Vaxigrip<sup>®</sup>
unintentionally contained a lower concentration of haemagglutinin (HA) than European Pharmacopoeia (EP) and WHO specifications for one of the three strains.</p>
<p><bold>Objectives </bold>
To evaluate the immunogenicity of the 2005 southern hemisphere formulation of an influenza vaccine containing 9 μg/dose of HA for A/Wellington/1/2004(H3N2) strain, and 15 μg/dose for each of the A/New Caledonia/20/99(H1N1) strain and B/Shanghai/361/2002‐like strains.</p>
<p><bold>Patients/methods </bold>
In an open, non‐controlled multicentre clinical trial, 75 healthy adults (18–59 years) and 65 healthy older adults (≥60 years) were vaccinated once. Serum samples were obtained on D0 and 21 for haemagglutination inhibition (HAI) antibody titration.</p>
<p><bold>Results </bold>
A high proportion of adults (64%) and elderly (68%) were already seroprotected (HAI titre of ≥40) against A/Wellington/1/2004(H3N2) before vaccination, probably due to high circulation of an antigenically similar H3N2 strain and a high 2004 vaccination rate. By D21, seroprotection rates against H3N2 attained 93·8% and 96·0% in adults and elderly respectively. The other two immunogenicity criteria for annual licensure of influenza vaccines in Europe were also met in both age groups for the H3N2 strain, and also for the H1N1 and B strains.</p>
<p><bold>Conclusions </bold>
These results enabled the 2005 southern hemisphere vaccine to be used in expectation that it would provide satisfactory protection against influenza, despite the reduced H3N2 antigen content.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Influenza Other Respir Viruses</journal-id>
<journal-id journal-id-type="iso-abbrev">Influenza Other Respir Viruses</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1750-2659</journal-id>
<journal-id journal-id-type="publisher-id">IRV</journal-id>
<journal-title-group><journal-title>Influenza and Other Respiratory Viruses</journal-title>
</journal-title-group>
<issn pub-type="ppub">1750-2640</issn>
<issn pub-type="epub">1750-2659</issn>
<publisher><publisher-name>Blackwell Publishing Ltd</publisher-name>
<publisher-loc>Oxford, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">19453468</article-id>
<article-id pub-id-type="pmc">4634696</article-id>
<article-id pub-id-type="doi">10.1111/j.1750-2659.2008.00039.x</article-id>
<article-id pub-id-type="publisher-id">IRV039</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group><article-title>Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine</article-title>
<alt-title alt-title-type="left-running-head">Burrell <italic>et al.</italic>
</alt-title>
<alt-title alt-title-type="right-running-head">Immunogenicity of reduced dose influenza vaccine</alt-title>
</title-group>
<contrib-group><contrib id="cr1" contrib-type="author"><name><surname>Burrell</surname>
<given-names>Christopher</given-names>
</name>
<xref ref-type="aff" rid="a1"><sup>1</sup>
</xref>
<xref ref-type="aff" rid="a2"><sup>2</sup>
</xref>
</contrib>
<contrib id="cr2" contrib-type="author"><name><surname>Booy</surname>
<given-names>Robert</given-names>
</name>
<xref ref-type="aff" rid="a3"><sup>3</sup>
</xref>
</contrib>
<contrib id="cr3" contrib-type="author"><name><surname>Wood</surname>
<given-names>Nicholas</given-names>
</name>
<xref ref-type="aff" rid="a3"><sup>3</sup>
</xref>
</contrib>
<contrib id="cr4" contrib-type="author"><name><surname>Egan</surname>
<given-names>Anne‐Marie</given-names>
</name>
<xref ref-type="aff" rid="a3"><sup>3</sup>
</xref>
</contrib>
<contrib id="cr5" contrib-type="author"><name><surname>Taverner</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="a4"><sup>4</sup>
</xref>
</contrib>
<contrib id="cr6" contrib-type="author"><name><surname>Williams</surname>
<given-names>Ken</given-names>
</name>
<xref ref-type="aff" rid="a5"><sup>5</sup>
</xref>
</contrib>
<contrib id="cr7" contrib-type="author"><name><surname>Liauw</surname>
<given-names>Winston</given-names>
</name>
<xref ref-type="aff" rid="a5"><sup>5</sup>
</xref>
</contrib>
<contrib id="cr8" contrib-type="author"><name><surname>Moskwa</surname>
<given-names>Alan</given-names>
</name>
<xref ref-type="aff" rid="a6"><sup>6</sup>
</xref>
</contrib>
<contrib id="cr9" contrib-type="author"><name><surname>Pepin‐Covatta</surname>
<given-names>Stephanie</given-names>
</name>
<xref ref-type="aff" rid="a7"><sup>7</sup>
</xref>
</contrib>
<contrib id="cr10" contrib-type="author"><name><surname>Saville</surname>
<given-names>Melanie</given-names>
</name>
<xref ref-type="aff" rid="a7"><sup>7</sup>
</xref>
</contrib>
</contrib-group>
<aff id="a1"><label><sup>1</sup>
</label>
School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, Australia</aff>
<aff id="a2"><label><sup>2</sup>
</label>
Infectious Diseases Laboratories, Institute of Medical and Veterinary Science, Adelaide, Australia</aff>
<aff id="a3"><label><sup>3</sup>
</label>
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead and the University of Sydney, NSW, Australia</aff>
<aff id="a4"><label><sup>4</sup>
</label>
Department of Pharmacology, The University of Adelaide, Adelaide, Australia</aff>
<aff id="a5"><label><sup>5</sup>
</label>
St Vincent’s Clinical Trials Centre, St Vincent’s Hospital, Darlinghurst, Australia</aff>
<aff id="a6"><label><sup>6</sup>
</label>
CMAX Royal Adelaide Hospital, Adelaide, Australia</aff>
<aff id="a7"><label><sup>7</sup>
</label>
Sanofi Pasteur, Marcy l’Etoile, France</aff>
<author-notes><corresp id="correspondenceTo">Stephanie Pepin‐Covatta, Sanofi Pasteur, 1541, Avenue Marcel Mérieux, F‐69280 Marcy l’Etoile, France. Email: <email>stephanie.pepin@sanofipasteur.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub"><day>28</day>
<month>6</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="ppub"><month>5</month>
<year>2008</year>
</pub-date>
<volume>2</volume>
<issue>3</issue>
<issue-id pub-id-type="doi">10.1111/irv.2008.2.issue-3</issue-id>
<fpage>93</fpage>
<lpage>98</lpage>
<history>Accepted 7 February 2008. Published Online 7 April 2008.</history>
<permissions><copyright-statement content-type="article-copyright">© 2008 The Authors. Journal Compilation © 2008 Blackwell Publishing Ltd</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:type="simple" xlink:href="file:IRV-2-093.pdf"></self-uri>
<abstract abstract-type="main"><p><bold>Background </bold>
The 2005 southern hemisphere formulation of the inactivated split‐virion influenza vaccine Vaxigrip<sup>®</sup>
unintentionally contained a lower concentration of haemagglutinin (HA) than European Pharmacopoeia (EP) and WHO specifications for one of the three strains.</p>
<p><bold>Objectives </bold>
To evaluate the immunogenicity of the 2005 southern hemisphere formulation of an influenza vaccine containing 9 μg/dose of HA for A/Wellington/1/2004(H3N2) strain, and 15 μg/dose for each of the A/New Caledonia/20/99(H1N1) strain and B/Shanghai/361/2002‐like strains.</p>
<p><bold>Patients/methods </bold>
In an open, non‐controlled multicentre clinical trial, 75 healthy adults (18–59 years) and 65 healthy older adults (≥60 years) were vaccinated once. Serum samples were obtained on D0 and 21 for haemagglutination inhibition (HAI) antibody titration.</p>
<p><bold>Results </bold>
A high proportion of adults (64%) and elderly (68%) were already seroprotected (HAI titre of ≥40) against A/Wellington/1/2004(H3N2) before vaccination, probably due to high circulation of an antigenically similar H3N2 strain and a high 2004 vaccination rate. By D21, seroprotection rates against H3N2 attained 93·8% and 96·0% in adults and elderly respectively. The other two immunogenicity criteria for annual licensure of influenza vaccines in Europe were also met in both age groups for the H3N2 strain, and also for the H1N1 and B strains.</p>
<p><bold>Conclusions </bold>
These results enabled the 2005 southern hemisphere vaccine to be used in expectation that it would provide satisfactory protection against influenza, despite the reduced H3N2 antigen content.</p>
</abstract>
<kwd-group><kwd id="k1">Antigen content</kwd>
<kwd id="k2">immunogenicity</kwd>
<kwd id="k3">inactivated vaccine</kwd>
</kwd-group>
<counts><fig-count count="0"></fig-count>
<table-count count="2"></table-count>
<page-count count="6"></page-count>
</counts>
<custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta><meta-name>cover-date</meta-name>
<meta-value>May 2008</meta-value>
</custom-meta>
<custom-meta><meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Booy, Robert" sort="Booy, Robert" uniqKey="Booy R" first="Robert" last="Booy">Robert Booy</name>
<name sortKey="Burrell, Christopher" sort="Burrell, Christopher" uniqKey="Burrell C" first="Christopher" last="Burrell">Christopher Burrell</name>
<name sortKey="Egan, Anne Arie" sort="Egan, Anne Arie" uniqKey="Egan A" first="Anne-Marie" last="Egan">Anne-Marie Egan</name>
<name sortKey="Liauw, Winston" sort="Liauw, Winston" uniqKey="Liauw W" first="Winston" last="Liauw">Winston Liauw</name>
<name sortKey="Moskwa, Alan" sort="Moskwa, Alan" uniqKey="Moskwa A" first="Alan" last="Moskwa">Alan Moskwa</name>
<name sortKey="Pepin Ovatta, Stephanie" sort="Pepin Ovatta, Stephanie" uniqKey="Pepin Ovatta S" first="Stephanie" last="Pepin-Covatta">Stephanie Pepin-Covatta</name>
<name sortKey="Saville, Melanie" sort="Saville, Melanie" uniqKey="Saville M" first="Melanie" last="Saville">Melanie Saville</name>
<name sortKey="Taverner, David" sort="Taverner, David" uniqKey="Taverner D" first="David" last="Taverner">David Taverner</name>
<name sortKey="Williams, Ken" sort="Williams, Ken" uniqKey="Williams K" first="Ken" last="Williams">Ken Williams</name>
<name sortKey="Wood, Nicholas" sort="Wood, Nicholas" uniqKey="Wood N" first="Nicholas" last="Wood">Nicholas Wood</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002987 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 002987 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Pmc |étape= Checkpoint |type= RBID |clé= PMC:4634696 |texte= Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:19453468" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |